Role of heat shock protein 27 in gemcitabine-resistant human pancreatic cancer: Comparative proteomic analyses

Molecular Medicine Reports

Volumn 6, Issue 4, 2012, Pages 767-773

  Liu, Qing Hua ^a,b   Zhao, Chen Yan ^a   Zhang, Jing ^a   Chen, Ying ^a   Gao, Li ^a   Ni, Can Yong ^a   Zhu, Ming Hua ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Gemcitabine; Heat shock protein 27; Intrinsic chemoresistance; Pancreatic cancer; Proteomics

Indexed keywords

GEMCITABINE; HEAT SHOCK PROTEIN 27;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOMA CELL; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PANCREAS ADENOCARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; STAINING; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYCYTIDINE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PANCREATIC NEOPLASMS; PROTEOME;

EID: 84865188440     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1013     Document Type: Article

References (34)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet 378: 607-620, 2011.
3. Kawanami T, Takiguchi S, Ikeda N and Funakoshi A: A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin. Oncol Rep 27: 867-872, 2012.
4. Kasuya K, Tsuchida A, Nagakawa Y, et al: Hypoxia-inducible factor-1alpha expression and gemcitabine chemotherapy. Oncol Rep 26: 1399-1406, 2011.
5. Chen H, Wei W, Guo Y, et al: Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis. Oncol Rep 25: 1253-1261, 2011.
6. Di Marco M, Di Cicilia R, Macchini M, et al: Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review). Oncol Rep 23: 1183-1192, 2010.
7. Burris HA, 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413, 1997. (Pubitemid 27251144)
8. Neoptolemos JP, Stocken DD, Bassi C, et al: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. Jama 304: 1073-1081, 2010.
9. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R and Bertino JR: Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 1587: 164-173, 2002. (Pubitemid 34657277)
10. Muerkoster S, Wegehenkel K, Arlt A, et al: Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 64: 1331-1337, 2004. (Pubitemid 38235601)
11. Yamauchi K, Yang M, Hayashi K, et al: Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res 68: 516-520, 2008. (Pubitemid 351380079)
12. Wu YJ, Muldoon LL, Dickey DT, Lewin SJ, Varallyay CG and Neuwelt EA: Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models. Neoplasia 11: 187-195, 2009.
13. Liu QH, Zhang J, Zhao CY, et al: Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer. Cancer Lett 314: 119-125, 2012.
14. Mosser DD and Morimoto RI: Molecular chaperones and the stress of oncogenesis. Oncogene 23: 2907-2918, 2004. (Pubitemid 38638852)
15. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E and Kroemer G: Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5: 2592-2601, 2006. (Pubitemid 44785803)
16. Zhao L, Liu L, Wang S, Zhang YF, Yu L and Ding YQ: Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins. J Cancer Res Clin Oncol 133: 771-782, 2007. (Pubitemid 47319243)
17. Kang SH, Kang KW, Kim KH, et al: Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. BMC Cancer 8: 286, 2008.
18. Larkin SE, Holmes S, Cree IA, et al: Identification of markers of prostate cancer progression using candidate gene expression. Br J Cancer 106: 157-165, 2012.
19. Xia Y, Liu Y, Wan J, et al: Novel triazole ribonucleoside down-regulates heat shock protein 27 and induces potent anticancer activity on drug-resistant pancreatic cancer. J Med Chem 52: 6083-6096, 2009.
20. Ciocca DR and Calderwood SK: Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 10: 86-103, 2005. (Pubitemid 40942470)
21. Soti C, Nagy E, Giricz Z, Vigh L, Csermely P and Ferdinandy P: Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 146: 769-780, 2005. (Pubitemid 41622243)
22. Schafer C, Seeliger H, Bader DC, et al: Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. J Cell Mol Med doi: 10.1111/j.1582-4934.2011.01473.x., 2011.
23. Berrieman HK, Cawkwell L, O'Kane SL, Smith L and Lind MJ: Hsp27 may allow prediction of the response to single-agent vinorelbine chemotherapy in non-small cell lung cancer. Oncol Rep 15: 283-286, 2006.
24. Yang YX, Xiao ZQ, Chen ZC, et al: Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR. Proteomics 6: 2009-2021, 2006.
25. Liao WC, Wu MS, Wang HP, Tien YW and Lin JT: Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. Pancreas 38: 422-426, 2009.
26. Leonardi R, Pannone G, Magro G, Kudo Y, Takata T and Lo Muzio L: Differential expression of heat shock protein 27 in normal oral mucosa, oral epithelial dysplasia and squamous cell carcinoma. Oncol Rep 9: 261-266, 2002.
27. Vargas-Roig LM, Gago FE, Tello O, Aznar JC and Ciocca DR: Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 79: 468-475, 1998. (Pubitemid 28445267)
28. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, et al: Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol 31: 1345-1350, 2007.
29. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, et al: A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Mol Med Report 1: 429-434, 2008.
30. Heinrich JC, Tuukkanen A, Schroeder M, Fahrig T and Fahrig R: RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients. J Cancer Res Clin Oncol 137: 1349-1361, 2011.
31. Arrigo AP: Hsp27: novel regulator of intracellular redox state. IUBMB Life 52: 303-307, 2001.
32. Nakashima M, Adachi S, Yasuda I, et al: Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells. Cancer Lett 313: 218-225, 2011.
33. Taba K, Kuramitsu Y, Ryozawa S, et al: Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells. Anticancer Res 30: 2539-2543, 2010.
34. Baylot V, Andrieu C, Katsogiannou M, et al: OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis 2: e221, 2011.